CBP-501 ACETATE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C86H122F5N29O17.C2H4O2
Molecular Weight	1989.1204
Optical Activity	UNSPECIFIED
Defined Stereocenters	12 / 12
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)=O.N[C@H](CC1=CC=C(C=C1)C(=O)C2=CC=CC=C2)C(=O)N[C@H](CO)C(=O)N[C@H](CC3=CNC4=C3C=CC=C4)C(=O)N[C@H](CO)C(=O)N[C@H](CC5=C(F)C(F)=C(F)C(F)=C5F)C(=O)N[C@H](CC6CCCCC6)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(O)=O

InChI

InChIKey=GKMPTIBZVGZJDN-RJLNLWLESA-N

InChI=1S/C86H122F5N29O17.C2H4O2/c87-64-49(65(88)67(90)68(91)66(64)89)39-60(118-80(135)62(42-122)120-77(132)59(38-47-40-109-51-19-8-7-18-48(47)51)117-79(134)61(41-121)119-70(125)50(92)36-44-25-27-46(28-26-44)69(124)45-16-5-2-6-17-45)78(133)116-58(37-43-14-3-1-4-15-43)76(131)113-54(22-11-33-106-84(98)99)72(127)110-52(20-9-31-104-82(94)95)71(126)111-53(21-10-32-105-83(96)97)73(128)114-56(29-30-63(93)123)75(130)112-55(23-12-34-107-85(100)101)74(129)115-57(81(136)137)24-13-35-108-86(102)103;1-2(3)4/h2,5-8,16-19,25-28,40,43,50,52-62,109,121-122H,1,3-4,9-15,20-24,29-39,41-42,92H2,(H2,93,123)(H,110,127)(H,111,126)(H,112,130)(H,113,131)(H,114,128)(H,115,129)(H,116,133)(H,117,134)(H,118,135)(H,119,125)(H,120,132)(H,136,137)(H4,94,95,104)(H4,96,97,105)(H4,98,99,106)(H4,100,101,107)(H4,102,103,108);1H3,(H,3,4)/t50-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C2H4O2
Molecular Weight	60.052
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C86H122F5N29O17
Molecular Weight	1929.0684
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	12 / 12
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25047675 | https://www.ncbi.nlm.nih.gov/pubmed/22223868 | https://www.ncbi.nlm.nih.gov/pubmed/22032894

CBP-501 is a chemically modified duodecapeptide and an analog of M-phase inducer phosphatase 3 (CDC25C) that increase cisplatin influx into tumor cells through an interaction with calmodulin enhancing cisplatin cytotoxicity, and affects cell cycle progression by abrogating DNA repair at the G2 checkpoint. CBP501 selectively inhibits the kinases MAPKAP-K2, C-TAK1, and CHK1 in vitro. Cell lines exposed to CBP501 plus bleomycin show a dose-dependent reduction of phosphorylated Ser216 on CDC25C. In addition to these effects on the G2 checkpoint, CBP501 also increases platinum concentration and DNA-platinum adduct formation in tumor cells through binding with calmodulin. In an in vitro panel testing the sensitivity of several tumor-derived cell lines to CBP501 in combination with a variety of anti-cancer agents, the combination of CBP501 with cisplatin was particularly effective against all four mesothelioma cell lines tested. Unfortunately, CBP-501 does not improve the efficacy of standard chemotherapy for malignant pleural mesothelioma.

Originator

Approval Year

PubMed

Title	Date	PubMed
Novel therapies in phase II and III trials for malignant pleural mesothelioma.	2012-01	22223868

Patents

Sample Use Guides

In Vivo Use Guide

CBP501 25 mg/m2 IV

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:58:23 GMT 2025` Edited by `admin` on `Mon Mar 31 17:58:23 GMT 2025`
Record UNII	8HSP55450P
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

CBP-501 ACETATE

Common Name

English

CBP501 ACETATE

Preferred Name

English

H-(D)P-BENZOYLPHENYLALANYL-(D)SERYL-(D)TRYPTOPHANYL-(D)SERYL-(D)PENTAFLUOROPHENYLALANYL-(D)CYCLOHEXYLALANYL-(D)ARGINYL-(D)ARGINYL-(D)ARGINYL-(D)GLUTAMINYL-(D)ARGINYL-(D)ARGININE ACETATE SALT

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

922322